Predex

Quick links to important sections

Predex

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Predex

Quick Facts

Property Description
Active Ingredients Prednisolone Acetate, Neomycin Sulfate, Polymyxin B Sulfate
Form Ophthalmic Suspension (sterile liquid drops)
Pharmacological Class Ophthalmic Steroids with Anti-infectives
Common Use Management of steroid-responsive inflammatory ocular conditions with bacterial risk
Origin Combination Product (Synthetic and Naturally Derived components)

What is Predex and What Type of Medicine is it?

Predex is defined as a specialized Steroid-Antibiotic Combination Product formulated as a sterile ophthalmic suspension for topical ocular use. This drug is classified within the pharmacological group of ophthalmic steroids with anti-infectives, a category clinically recognized for providing combination therapy. Predex is a prescription-only combination product containing three active ingredients, making it fundamentally distinct from single-agent eye drops. It is specifically engineered to concurrently manage two clinical needs: controlling inflammation and mitigating the risk or presence of bacterial infection.

Composition, Active Ingredients, and Form

The medicine is composed of three distinct active ingredients: the potent corticosteroid Prednisolone Acetate, alongside the two antibiotics, Neomycin Sulfate (an aminoglycoside) and Polymyxin B Sulfate (a polymyxin). The Prednisolone component is a synthetic glucocorticoid designed for potent local effect. The combination of these two distinct antibiotic classes enhances coverage against a broader spectrum of susceptible bacteria. The final dosage form is an ophthalmic suspension, which requires adequate agitation before application to ensure uniform delivery of the components during topical ocular administration.

What is the General Therapeutic Purpose of This Combination?

The general therapeutic purpose of Predex is to provide a comprehensive, dual-action approach to stabilize the ocular environment, supported by decades of clinical practice in managing complex eye issues. This combination quickly addresses the symptom relief from redness, swelling, and irritation via Prednisolone. Simultaneously, the dual antibiotics offer targeted defense by eliminating or preventing the growth of susceptible bacteria, thereby supporting the success of the primary anti-inflammatory treatment. This concurrent action ensures that both key factors—inflammation and bacterial risk—are managed by one medication.

What side effects are possible with Predex?

Possible side effects and safety information

The safety profile of the prednisolone-neomycin-polymyxin B ophthalmic suspension is based on the documented effects of topical ocular corticosteroids and the specific antibiotic components, as outlined in government regulatory sources.

Ocular-Specific Adverse Reactions

Adverse reactions classified as common upon instillation include transient ocular stinging and burning. The most significant serious adverse reaction is the potential for Elevated Intraocular Pressure (IOP), which may lead to the development of glaucoma and subsequent optic nerve damage and visual acuity defects. Prolonged use is also specifically associated with the formation of a Posterior Subcapsular Cataract.

In cases where the cornea or sclera is thinned by disease, the use of topical steroids carries a risk of perforation of the globe. Other documented ocular effects include blurred vision and localized irritation.

Time-Related Safety Patterns and Restrictions

Safety concerns are often linked to the duration of exposure. Prolonged use is the pattern associated with the development of both glaucoma and cataract formation. A high-level safety pattern also dictates that the corticosteroid component may mask, enhance, or exacerbate a pre-existing ocular infection, necessitating careful management.

Due to the neomycin component, there is a risk of allergic sensitization and hypersensitivity reactions. The product is officially contraindicated in most viral diseases of the cornea and conjunctiva, as well as in mycobacterial and fungal diseases of ocular structures, reflecting the potential for severe safety consequences in these conditions.

Population-Specific Notes

The label includes safety notes regarding use in pediatric patients, where the risk of steroid-induced ocular hypertension may be greater. Special consideration is required during pregnancy and lactation based on potential systemic exposure concerns.

Overdose and Emergency Response

The official regulatory profile for overdose of this ophthalmic suspension (Prednisolone Acetate, Neomycin Sulfate, Polymyxin B Sulfate) focuses primarily on necessary emergency actions due to the low risk of acute systemic toxicity from topical use. Documented manifestations of overdose or overuse center on severe localized Hypersensitivity Reactions, which may present as reddiness (erythema), itching, and swelling (edema) of the eyelid and conjunctiva.

Severe outcomes listed in regulatory documents that necessitate urgent care include potential anaphylaxis and other life-threatening allergic reactions, which may involve difficulty breathing or swelling of the face, tongue, or throat. Immediate medical attention is required if these severe allergic signs occur.

The regulator mandates that individuals should call Poison Control or emergency services immediately if accidental ingestion or the application of too much medication has occurred. If symptoms persist or worsen, the use of the product should be discontinued.

Regarding management, no specific antidote is documented in the prescribing information for this topical combination. Consequently, overdose treatment is described as being symptomatic and supportive. Regulatory warnings also note that prolonged, excessive exposure to the corticosteroid component carries the risk of systemic effects, such as signs of Systemic Hypercorticoidism or Adrenal Suppression. Population-specific warnings advise monitoring for Hypoadrenalism in infants exposed to substantial systemic doses.

Therapeutic Uses of Predex

What Predex Treats: Main Uses and Benefits

The combination is applied in addressing conditions where inflammation is steroid-responsive and a concurrent bacterial risk exists. These products may be considered relevant when both a corticosteroid and an anti-infective are appropriate. This type of therapy is considered relevant in specific ocular conditions.

This medication may assist with managing symptom clusters that may become intense, such as redness, swelling, and edema, or symptoms related to inflammatory or irritative states. The conditions it helps manage include chronic anterior uveitis, inflammatory conditions of the cornea and conjunctiva, and corneal injury resulting from foreign bodies or burns. This dual management approach supports the patient during difficult episodes by easing distress and is relevant for easing symptoms that become more disruptive during flare-ups.


Quick Fact: Relief for Inflammatory Discomfort

This therapy contributes to improved day-to-day comfort during periods of heightened symptoms, and provides supportive relief when symptoms interfere with routine activities, helping to ease the overall symptom load.

Eligibility and Restrictions for Use

Eligibility Scope

Classification Population Status Defined by Regulators
Contraindicated Viral diseases of the cornea and conjunctiva (e.g., Herpes Simplex Keratitis, Vaccinia, Varicella) Must not use
Contraindicated Mycobacterial or Fungal diseases of ocular structures Must not use
Contraindicated Known or suspected hypersensitivity to Prednisolone, Neomycin, Polymyxin B, or any component Must not use
Restricted Use Patients with Glaucoma or a history of Herpes Simplex infection of the eye Use with caution and frequent monitoring
Use Not Established Pediatric patients (under 18 years of age) Safety and effectiveness not established

Official Population Eligibility

The medicine is contraindicated and must not be used by individuals with certain active ocular infections, including most viral, mycobacterial, or fungal diseases of the eye, or by anyone with a confirmed allergy to any of the preparation’s ingredients. Use is established for adults and older adult (geriatric) patients. For pediatric patients, use is not recommended as the safety and effectiveness of this specific combination have not been formally established.

Pregnancy and Lactation Status

Use during pregnancy is advised only if the potential benefit justifies the potential risk to the fetus, as the corticosteroid component has shown teratogenic effects in animal studies (Pregnancy Category C). For lactation, regulatory documents state a decision must be made to discontinue nursing or discontinue the drug due to the potential for adverse effects from systemically absorbed corticosteroids appearing in human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for this ophthalmic suspension is based on documented effects related to its active components: prednisolone acetate, neomycin sulfate, and polymyxin B sulfate. The most significant pharmacokinetic interaction involves the corticosteroid component.

Pharmacokinetic and Pharmacodynamic Interactions

Category Interacting Substance/Class Official Regulatory Description
Exposure Modification CYP3A4 Inhibitors (e.g., Ritonavir, Cobicistat) Co-treatment may significantly increase systemic exposure to the prednisolone component, raising the potential for systemic effects.
Additive Pharmacodynamic Effect Topical NSAIDs Concomitant use is officially associated with an increased potential for corneal healing problems through an additive effect.
Cross-Reactivity Risk Other Aminoglycoside Antibiotics The neomycin sulfate component carries a documented potential for allergic cross-reactions with other systemic or topical aminoglycosides.

Administration Timing Constraints

Official prescribing information notes that the concurrent use of this product with any other ophthalmic products requires an appropriate time separation between administrations. This procedural requirement is necessary to prevent the dilution or physical washout of the ophthalmic suspension, ensuring the drug components remain in contact with the eye surface for the intended duration.

No interactions with food, alcohol, or herbal products are explicitly documented in regulatory labels for this topical combination product.

Mechanism of Action

How Predex Works: Mechanism of Action

Predex (dexmedetomidine) exerts its primary action as an agonist (activator) of the alpha2-adrenergic receptor, particularly the alpha2 A subtype, which are G-protein coupled receptors. Binding to these receptors initiates an inhibitory signaling cascade, resulting in the suppression of the release of the excitatory neurotransmitter norepinephrine (noradrenaline).

This mechanism operates across two main physiological domains. Centrally, activation of alpha2-receptors in the Locus Coeruleus inhibits the firing of noradrenergic neurons, which contributes to a state of decreased arousal and preserved arousability. Concurrently, alpha2-receptor activation in the spinal cord dorsal horn modifies pain signal transmission, resulting in pain signal attenuation.

Systemically, the reduction in central sympathetic outflow and peripheral norepinephrine release leads to a sympatholytic effect. This modulation of autonomic regulation contributes to a reduction in heart rate (chronotropic effect) and a decrease in blood pressure (vasomotor effect).

Dosage and Administration Information

Administration Overview

Predex is typically administered as an ophthalmic solution. Proper technique is essential to ensure the medication is delivered effectively to the ocular surface and to minimize the risk of contamination.

General Application Steps

To apply the drops, the head is usually tilted back slightly while the lower eyelid is gently pulled down to create a small pocket. The dropper tip is positioned over the eye without making direct contact with the eye, eyelid, or any other surface. After the drop is instilled, the eye is closed gently.

Maintaining Product Integrity

To maintain the sterility of the solution, the dropper tip must not touch any surface. The cap should be replaced and tightened immediately after each use. If the solution changes color or becomes cloudy, it should not be used.

Use with Contact Lenses

Contact lenses are generally removed prior to the administration of the drops. Guidance regarding the reinsertion of lenses depends on the specific formulation and the underlying condition being treated.

Consistency in Use

The medication is most effective when used at regularly spaced intervals as determined by a healthcare provider. If more than one type of ophthalmic medication is being used, a period of several minutes is typically observed between the application of different products to prevent the second drop from washing out the first.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Predex

This overview summarizes the structure and reported findings of research studies for Predex (a combination ophthalmic suspension containing a corticosteroid and two antibiotics) as evaluated by regulatory and scientific bodies. The information describes what was studied, the outcomes that were measured, and where research is still developing, without providing medical advice or recommendations.


Evidence for Use in Steroid-Responsive Inflammatory Conditions with Bacterial Risk

Research into this type of combination therapy has been conducted through Randomized Controlled Trials (RCTs) and comparative studies. These studies carried out during periods of increased symptom activity research examined how symptoms evolved in populations that require both inflammation control and addressing bacterial risk. The primary focus was monitoring outcomes linked to inflammatory or irritative states, alongside tracking the status of potential or present bacterial cultures.

Studies reported measurements of clinical success based on investigator criteria, focusing on short-term changes during the acute treatment period. The existence of this research provides regulatory context. Findings were consistent with the established regulatory indication for dual-component medication used in conditions involving both inflammation and susceptible bacterial risk. However, follow-up durations were limited, typically lasting 7 to 14 days, which is consistent with the timeframe for acute ocular treatment.


Research in Conjunctival and Corneal Inflammation

Studies explored how symptoms related to redness, swelling, and irritation were measured in adults with acute inflammation of the conjunctiva and cornea. Researchers monitored outcomes related to inflammation resolution and, where applicable, assessed bacterial clearance.

Research highlights changes measured, reporting patterns observed in the management of inflammation. Much of the foundational evidence for this type of generic combination product has varying quality across studies, and many recent large-scale trials have utilized newer formulations instead of this specific combination. The evidence base indicates that the research scope is conditional on the susceptibility of the local bacteria to the specific antibiotics (Neomycin and Polymyxin B) present in the formulation.


What is Still Uncertain About Predex Research

Several limitations exist in the current research landscape. Comparative evidence is lacking for a direct, head-to-head comparison of this specific generic formulation against all contemporary alternatives, making it difficult to contextualize its role precisely among newer treatments. Furthermore, the research scope related to infection is limited by the local bacterial sensitivity to Neomycin and Polymyxin B; a potential limitation is that resistance patterns may change over time. Finally, long-term effects are not fully established by dedicated randomized trials, as most research focuses on acute treatment periods.

Frequently Asked Questions (FAQ)

Common questions about Predex (FAQ)


Q: What category of drug does Predex belong to?

Predex is officially classified within the pharmacological group of Ophthalmic Steroids with Anti-infectives. This category is defined for combination drugs that concurrently address both inflammation and the potential for bacterial infection in the eye.


Q: How is Predex different from similar drugs used for the same purpose?

Predex is officially defined in regulatory documents as a combination sterile ophthalmic suspension. Unlike single-agent eye drops, it is formulated with three active ingredients: a corticosteroid to address inflammation and two distinct antibiotics to mitigate bacterial risk.


Q: Does Predex cause drowsiness, or is it a different kind of feeling?

Official safety information for this topical ophthalmic product does not list systemic effects like drowsiness or sleepiness as common side effects. The most common sensations reported are localized to the eye, such as transient stinging and burning immediately after the drops are instilled.


Q: Is it common to feel dizzy or lightheaded after receiving Predex?

The most commonly reported effects of this topical medication are localized ocular reactions, as described in regulatory documents. Systemic effects such as dizziness or lightheadedness are not specified as common side effects in the official prescribing information.


Q: What kind of severe side effects are mentioned in the official safety information for Predex?

Serious adverse reactions mentioned in official safety documents include the potential for elevated intraocular pressure (IOP), which may lead to glaucoma. Prolonged use is also associated with the formation of cataracts. A safety concern noted is the risk of globe perforation in eyes where the tissue is already thinned by disease.


Q: Can Predex affect my breathing or heart rate?

Official safety information for this topical product primarily lists localized effects on the eye. Any impact on breathing or heart rate would only be a concern if significant systemic absorption of the corticosteroid occurred, which is not commonly reported for the ophthalmic route.


Q: What happens if Predex is mixed with other medications that cause sleepiness?

Regulatory labels do not document any known interaction between this topical ophthalmic product and other medications that may cause sleepiness. The identified drug interactions relate only to specific enzyme inhibitors or other ophthalmic products.


Q: How long does it typically take for the effects of Predex to be noticeable?

The prednisolone component is intended to quickly begin addressing symptoms of inflammation. Clinical effects are typically measured over the short-term treatment period described in the official instructions. Localized relief from irritation may become noticeable shortly after administration.


Q: How long does Predex stay in the body after administration is stopped?

Regulatory documents indicate that the majority of the drug remains localized to the eye. Only a small, generally minimal amount of the active ingredients is systemically absorbed into the bloodstream, indicating the exposure is primarily confined to the local site.


Q: Is the term 'sedation' the same thing as being fully asleep when talking about Predex?

Predex is classified as an ophthalmic steroid-antibiotic combination product. Its intended use is to treat eye conditions and it is not classified as a sedative or an anesthetic. Therefore, its use is not associated with inducing a state of sedation or being fully asleep.


Q: Why are patients sometimes monitored closely after stopping Predex?

The official administration instructions describe that the frequency of use must be gradually reduced, or tapered, as the inflammatory condition subsides. This process is used to prevent a sudden return or recurrence of the symptoms the drug was initially treating.


Q: Why is Predex only available through certain types of healthcare providers or pharmacies?

Predex is classified in regulatory documents as a prescription-only medication. This designation means its sale and dispensing are restricted and require a valid prescription from a licensed healthcare provider.


Q: Is Predex considered a controlled substance?

Predex is classified as a prescription-only drug. However, according to regulatory scheduling lists, it is not designated as a controlled substance.


Q: Do patients typically remember what happened while they were receiving Predex?

As a topical eye drop, Predex is not designed to alter consciousness or brain function. Its use is not associated with effects on memory or the inability to recall events.


Q: Are allergic reactions to Predex common?

Official safety information notes a potential for allergic sensitization or hypersensitivity reactions, particularly due to the neomycin antibiotic component. Official information states the severity of these reactions can vary.


Q: Can Predex cause changes in blood pressure?

Regulatory documents list ocular and possible systemic corticosteroid effects. However, they do not specifically list changes in blood pressure as a reported adverse effect for this product when used via the topical ophthalmic route.


Q: Does the official information mention any risks of dependency or withdrawal with Predex?

Official prescribing information does not associate this drug with risks of chemical dependency or a true withdrawal syndrome. The requirement to gradually reduce the dose is intended to prevent the recurrence of the underlying inflammatory condition.


Q: Are there any warnings about driving or operating machinery after receiving Predex?

Regulatory warnings state that individuals should avoid driving or operating machinery until clear eyesight has returned, as the ophthalmic suspension may cause temporary blurred eyesight immediately after it is instilled.


Q: Does Predex contain any ingredients that might cause a reaction in people with known allergies?

Yes. The product is contraindicated for known hypersensitivity to any component. Inactive ingredients like sodium bisulfite and benzalkonium chloride are listed in official documents and may cause allergic-type reactions in susceptible individuals.


Q: Is it possible for Predex to cause a patient's pain perception to change?

The medication's primary action is to reduce inflammation, which indirectly provides relief from associated irritation and pain. The drug is not classified as an analgesic (painkiller) designed to directly alter nerve-based pain perception.


Q: Do official documents mention any potential for Predex to interact with herbal supplements?

Official regulatory labels and prescribing information for this topical product do not explicitly document or mention any known interactions with herbal supplements.


Q: Can Predex be used in patients who are mechanically ventilated?

Predex is a topical ophthalmic suspension (eye drops) used for specific eye conditions. It is not indicated or intended for use in intensive care settings or on patients who are mechanically ventilated.

How should Predex be stored and disposed of?

How to Store and Dispose of Predex (Prednisolone Acetate, Neomycin, Polymyxin B)

Official regulatory guidelines require Predex Ophthalmic Suspension to be stored at controlled room temperature, specifically between 15 C and 25 C (59 F and 77 F). The product must be protected from freezing and heat above 40 C.

Handling and Stability

The container must be kept tightly closed and stored upright. Because it is a suspension, the bottle must be shaken well before each use. To maintain sterility, avoid touching the dropper tip to any surface. For safety, always keep the medication out of the reach of children.

Disposal

Discard any remaining drops after the prescribed course of treatment. Do not flush Predex down a sink or toilet. Unused or expired medication should be disposed of by mixing it with an undesirable substance, sealing it in a bag, and placing it in the household trash, or by utilizing a drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Predex found in:

A-Z Index: